US2014294921A1PendingUtilityA1
Composition for tipical use for treating skin disorders
Est. expiryDec 9, 2030(~4.4 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 37/06A61P 29/00A61K 9/0014A61K 31/16A61P 17/10A61P 17/04A61K 31/205A61K 31/4188A61K 31/164A61P 17/18A61K 31/355A61P 17/08A61P 17/02A61P 17/06A61K 31/714A61K 31/045A61K 31/221A61P 17/00
33
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
It is described a composition, topically administrable, comprising as active ingredients L-carnitine or a derivative thereof, biotin, and at least one or more of the following active ingredients: vitamin B 12; vitamin E; bisabolol; and panthenol; useful for treating skin disorders.
Claims
exact text as granted — not AI-modified1 . Composition, for topical use, comprising as active ingredients L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts; biotin; and one ore more of the following active ingredients: vitamin B 12, vitamin E, bisabolol and panthenol.
2 . Composition of claim 1 , comprising as active ingredients L-carnitine; biotin; vitamin E; bisabolol; and panthenol.
3 . Composition of claim 1 , comprising as active ingredients L-carnitine; Biotin and vitamin B 12.
4 . Composition of claim 1 , wherein:
L-carnitine or a derivative thereof is present in an amount of from 0.1 to 20% by weight; or a derivative thereof is present in an amount of from 0.01 to 20% by weight; vitamin B 12 or a derivative thereof is present in an amount of from 0.001 to 10% by weight; vitamin E or a derivative thereof is present in an amount of from 0.01 to 10% by weight; bisabolol or a derivative thereof is present in an amount of from 0.01 to 20% by weight; and panthenol or a derivative thereof is present in an amount of from 0.01 to 20% by weight.
5 - 6 . (canceled)
7 . Method of preventing and/or treating inflammatory and/or degenerative disturbances of the skin with the composition of claim 1 in patients in need thereof comprising
administering to said patients an effective amount of the composition of claim 1 and
treating said patients of said inflammatory and/or degenerative disturbances of the skin.
8 . Composition of claim 7 , in which the disturbance of the skin is selected from the group consisting of: erythematous, inflammatory, allergic, autoimmune and oxidative disturbance of the skin.
9 . Composition of claim 7 , in which the disturbance of the skin is selected from the group consisting of: dermatitis or dermatoses.
10 . Composition of claim 1 , further comprising coenzymes, antioxidants, vitamins, mineral salts and solar filter.
11 . Composition of claim 1 , in the form of ointments, creams, lotions baths, solutions powders, gels, or in liposome form.
12 . Composition of claim 1 , in which the pharmaceutically acceptable salt of L-carnitine or alkanoyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.